Related Experiment Video
Updated: May 5, 2026

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Shp1 phosphatase regulates CXCR2 protein stability and IL8-mediated invasiveness in breast cancer
Marcello Monti1, Pier Giorgio Amendola2, Angela Filograna1
1Institute of Endotypes in Oncology, Metabolism and Immunology "G. Salvatore", National Research Council, Naples, Italy.
Abstract:
Shp1 is a cytosolic tyrosine phosphatase generally associated with antitumor effects through the inhibition of tyrosine kinase signaling. Herein, we shown that genetic and pharmacological inhibition of Shp1 in breast cancer cells induces accelerated cell migration and promotes a more invasive phenotype. Furthermore, we found that interleukin-8 (IL8), a chemokine with multiple pro-tumorigenic roles within the tumor microenvironment, directly modulates Shp1 activity. In breast cancer, IL8 elicits its functions through the binding to the CXCR2 receptor with the subsequent modulation of several intracellular signaling pathways. We show that in breast MCF7 cells, IL8 induces the PKC-mediated phosphorylation of Shp1 at Ser591, diminishing its enzymatic activity and impairing the dephosphorylation of PP2A; this enhances CXCR2 phosphorylation and alters receptor trafficking by promoting ubiquitination and degradation of CXCR2. This feedback mechanism limits IL8 signaling revealing a previously unrecognized mechanism of receptor turnover and signal attenuation. In addition, we found that Shp1-mediated regulation of CXCR2 directly influences IL8-driven invasiveness in a subtype-specific manner, affecting luminal and triple-negative breast cancer (TNBC) cells but not HER2-positive ones. Transcriptomic and pathway analyses further support Shp1 involvement in cytokine and GPCR signaling, particularly in TNBC, where its downregulation correlates with reduced survival and higher IL8 levels. Taken together, our findings elucidate a novel mechanism of IL8 signaling and identify Shp1 as a promising therapeutic target, highlighting the potential of modulating the CXCR2-Shp1 axis to limit invasiveness and metastasis in aggressive breast cancer subtypes, particularly TNBC.
Insights
Inhibiting Shp1 phosphatase in breast cancer accelerates cell migration and invasiveness. Interleukin-8 (IL8) reduces Shp1 activity, impacting receptor turnover and promoting metastasis, especially in triple-negative breast cancer (TNBC).
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Shp1 phosphatase typically inhibits tumor growth by suppressing tyrosine kinase signaling.
- Interleukin-8 (IL8) is a chemokine implicated in promoting tumor progression within the tumor microenvironment.
- IL8 exerts its pro-tumorigenic effects via the CXCR2 receptor, influencing intracellular signaling pathways.
Purpose of the Study:
- To investigate the role of Shp1 in breast cancer cell migration and invasiveness.
- To elucidate the mechanism by which IL8 modulates Shp1 activity.
- To identify Shp1 as a potential therapeutic target in aggressive breast cancer subtypes.
Main Methods:
- Genetic and pharmacological inhibition of Shp1 in breast cancer cell lines (MCF7).
- Analysis of IL8-induced signaling pathways, including PKC-mediated phosphorylation of Shp1 and CXCR2.
- Assessment of receptor ubiquitination, degradation, and cell invasiveness.
- Transcriptomic and pathway analyses.
Main Results:
- Shp1 inhibition enhances breast cancer cell migration and invasiveness.
- IL8 directly reduces Shp1 enzymatic activity through PKC-mediated phosphorylation at Ser591.
- This interaction leads to enhanced CXCR2 phosphorylation, ubiquitination, and degradation, creating a feedback loop for signal attenuation.
- Shp1's regulation of CXCR2 impacts IL8-driven invasiveness in a subtype-specific manner, notably affecting luminal and TNBC cells.
- Shp1 downregulation correlates with reduced survival and elevated IL8 levels in TNBC.
Conclusions:
- Shp1 plays a critical role in regulating IL8 signaling and breast cancer cell invasiveness.
- A novel feedback mechanism involving Shp1, IL8, and CXCR2 turnover has been identified.
- Targeting the CXCR2-Shp1 axis presents a promising therapeutic strategy for limiting invasiveness and metastasis in aggressive breast cancers, particularly TNBC.
Related Concept Videos
Hedgehog Signaling Pathway
Inhibition of Cdk Activity
Regulation of Angiogenesis and Blood Supply
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...

